Esta traducción se está preparando. Mientras tanto, mostramos temporalmente la versión original en inglés.
Regulación y derecho · 22/9/20161 min de lectura
Prospective Grant of Exclusive Patent License: Development of an Antibody-Drug Conjugate for Use in PhotoImmunoTherapy
Traducción automática local · Idioma original de la fuente
Resumen
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the U.S. Patents and Patent Applications listed in the Summary Information section of this notice to Aspyrian Therapeutics, Inc. ("Aspyrian") located in San Diego, California USA.
Idioma original de la fuente: Federal Register — All DocumentsAbrir el comunicado original →